DermaXon received a Phase 1 STTR Grant funding from the National Institute of Neurological Disorders and Stroke to support preclinical efficacy studies for a novel drug treatment for ichthyosis.
This award titled “Topical selective T-type blockers for the treatment of neuropathic pain” provides critical support of a research project which examines the efficacy of DermaXon’s technology platform for the treatment of peripheral neuropathy. This award has the potential to increase to $1.5 million, if the Phase 1 project is successful. Therapeutic activity of the antineoplastic agent paclitaxel is impaired by significant occurrence of sensory neuropathy resulting in treatment delay, dose modification, and in severe cases, discontinuation of the treatment impacting patient outcome. Our objective in this proposal is to design and deliver topically calcium channel blockers that will decrease abnormal neuronal hyperactivity and, examine their potential as novel therapeutic agents to treat paclitaxel-induced neuropathy.
DermaXon presented at the 2018 Society for Investigative Dermatology Annual meeting, May 2018, Orlando, USA. Results presented confirmed the efficacy of our one of CYP26 inhibitors in modulating epidermal barrier function.
DermaXon won the “Shark Tank” pitching competition at the Society for Investigative Dermatology 2017 annual meeting.
DermaXon presented at the 2017 Society for Investigative Dermatology Annual Meeting, May 2017, Portland, USA. Results presented confirmed the efficacy of our CYP26 inhibitors in organotypic model of Darier’s disease.
Dr. Philippe Diaz, C.S.O, presented at the 3rd Annual Drug Discovery USA Congress, October 2016, San Diego, USA. This meeting was focused on drug discovery strategies. Program
DermaXon received a Phase 1 STTR Grant funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases to support preclinical efficacy studies for a novel drug treatment for ichthyosis.
This award titled “Selective Inhibition of CYP26A1 in the Skin for the Treatment of Ichthyosis” provides critical support of a research project which examines the efficacy of DermaXon’s technology platform for the treatment of ichthyosis. This award has the potential to increase to $1.5 million, if the Phase 1 project is successful. The platform combines Cytochromes P450 (CYPs) inhibitors and gene expression profiling to identify more efficient and compliant treatments for skin diseases. DermaXon will compare the effect of approved and experimental drugs with their CYP26 inhibitors to mitigate hyperkeratosis associated with ichthyosis.
DermaXon Announces Publication of Article Describing Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26. Abstract
DermaXon Announces Publication of Article Showing Tazarotenic Acid is Substrate of Human Retinoic Acid Hydroxylase CYP26A1 and CYP26B1. Abstract
We are currently designing and developing a novel and effective anti-ageing skincare products line based on our unique scientific expertise in dermatology and physiological processes associated with ageing.
DermaXon was awarded a grant from The Montana Board of Research and Commercialization Technology for the development of a new treatment for skin disease.
DermaXon has been selected by the Center for Commercialization of the University of Washington to present the company at the University of Washington Innovation Open House.